Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-ESBL IgY
- Development stage
- Phase 2
- Lead developer
- Uppsala University
- Modality
- Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
Anti-ESBL IgY is an oral biologic therapy composed of polyclonal chicken egg yolk-derived immunoglobulin Y (IgY) antibodies. It is specifically engineered to target and neutralize extended-spectrum beta-lactamase (ESBL)-producing bacteria, primarily *Klebsiella pneumoniae* and *Escherichia coli*, within the gastrointestinal tract. Developed by researchers at Uppsala University, the drug is intended to eradicate intestinal carriage of these antibiotic-resistant pathogens, thereby reducing the risk of endogenous infection and horizontal transmission. Although it reached Phase II clinical testing, the trial was terminated early due to challenges in patient recruitment and high mortality in the target population.
- Other names
- anti-ESBL IgY antibodiesavian polyclonal anti-ESBL IgY
02
Targets
pathogenic E. coli (Pathogenic Escherichia coli)Class A BL (Class A beta-lactamase)
Beyond the preview
Go deeper on Anti-ESBL IgY.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-ESBL IgY.